Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.

Official Title
-----------------
RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement

Conditions
-----------------
Venous Thromboembolism

Intervention / Treatment
-----------------
* Drug: Rivaroxaban (BAY59-7939)
* Drug: Enoxaparin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients aged 18 years or above Patients scheduled for elective total hip replacement Exclusion Criteria: Planned, staged total bilateral hip replacement Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Rivaroxaban (BAY59-7939)<br>* 10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days<br>|
| Active Comparator: Arm 2<br> | Drug: Enoxaparin<br>* Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite endpoint of total VTE i.e.: Any DVT (proximal and/or distal), Non fatal PE, Death of all causes |  | Treatment period : up to day 36+/-6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of the composite endpoint comprising proximal DVT, non-fatal PE and VTE- related death (major VTE) |  | Treatment period : up to day 36+/-6 | 
| Incidence of symptomatic VTE (DVT, PE) |  | Treatment period : up to day 36+/-6 | 
| Incidence of DVT (total, proximal, distal) |  | Treatment period : up to day 36+/-6 | 
| Incidence of symptomatic VTE during follow-up |  | Follow-up period: following 36+/-6 days | 
| The composite endpoint comprising major VTE and treatment-emergent major bleeding |  | For major VTE, treatment period: up to Day 36+/-6 ; for major bleeding, from first dose of double-blind study medication to up to two days after last dose of double-blind study medication | 
| Incidence of the composite endpoint that results from the primary endpoint by substituting VTE related death for all death |  | Treatment period : up to day 36+/-6 | 
| Incidence of the composite endpoint that results from major VTE by substituting all cause mortality for VTE-related death |  | Treatment period : up to day 36+/-6 | 
| Treatment-emergent major bleedings |  | From first dose of double-blind study medication to up to two days after last dose of double-blind study medication | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention, Thromboembolism